High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleotides (original) (raw)

A high-performance liquid chromatographic (HPLC) assay has been developed for monitoring plasma thalidomide concentrations in patients with chronic graft-versus-host disease (GVHD). The assay is simple, using 0.5 mL of plasma, has a linear detection range up to 10 mg/L, and an impressive detection limit of 0.2 mg/L. The study indicates that thalidomide in plasma requires immediate analysis due to instability, but can be stabilized for lengthy periods through acidification, allowing for effective monitoring without adverse side effects.